|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4150 SGD | 0.00% |
|
-4.60% | +6.41% |
| 05-04 | Mirum Pharmaceuticals Announces Primary Endpoint Met In VISTAS Study Of Volixibat In Patients With Primary Sclerosing Cholangitis | CI |
| 04-09 | PSC Names CEO | MT |
Company Valuation: Corporation Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 160.5 | 232.4 | 174.3 | 171.8 | 179.9 | 212.7 |
| Change | - | 44.83% | -25% | -1.47% | 4.76% | 18.18% |
| Enterprise Value (EV) 1 | 77.26 | 129.9 | 58.52 | 47.19 | 62.41 | 73.67 |
| Change | - | 68.15% | -54.96% | -19.37% | 32.26% | 18.05% |
| P/E | 7.21x | 11.9x | 8.95x | 7.93x | 7.91x | 9.83x |
| PBR | 0.55x | 0.75x | 0.56x | 0.53x | 0.53x | 0.61x |
| PEG | - | -1x | -20.28x | 0.6x | 1.57x | -2x |
| Capitalization / Revenue | 0.34x | 0.44x | 0.32x | 0.36x | 0.37x | 0.45x |
| EV / Revenue | 0.16x | 0.24x | 0.11x | 0.1x | 0.13x | 0.15x |
| EV / EBITDA | 1.56x | 2.62x | 1.22x | 0.95x | 1.28x | 1.58x |
| EV / EBIT | 2.13x | 3.62x | 1.84x | 1.4x | 1.96x | 2.49x |
| EV / FCF | 4.08x | 51.5x | 2.02x | 1.36x | 2.13x | 3.38x |
| FCF Yield | 24.5% | 1.94% | 49.6% | 73.6% | 47% | 29.6% |
| Dividend per Share 2 | 0.005 | 0.0075 | 0.0125 | 0.013 | 0.018 | 0.02 |
| Rate of return | 1.72% | 1.79% | 3.97% | 4.13% | 5.45% | 5.13% |
| EPS 2 | 0.0402 | 0.0354 | 0.0352 | 0.0397 | 0.0417 | 0.0397 |
| Distribution rate | 12.4% | 21.2% | 35.5% | 32.7% | 43.2% | 50.4% |
| Net sales 1 | 471.4 | 533.3 | 553 | 482.1 | 488.6 | 477.2 |
| EBITDA 1 | 49.53 | 49.55 | 48.08 | 49.42 | 48.76 | 46.77 |
| EBIT 1 | 36.27 | 35.86 | 31.83 | 33.68 | 31.81 | 29.64 |
| Net income 1 | 22.25 | 19.57 | 19.49 | 21.8 | 22.75 | 21.62 |
| Net Debt 1 | -83.23 | -102.5 | -115.8 | -124.6 | -117.5 | -139 |
| Reference price 2 | 0.2900 | 0.4200 | 0.3150 | 0.3150 | 0.3300 | 0.3900 |
| Nbr of stocks (in thousands) | 553,416 | 553,416 | 553,416 | 545,297 | 545,297 | 545,297 |
| Announcement Date | 4/6/21 | 4/5/22 | 4/11/23 | 4/8/24 | 4/8/25 | 4/8/26 |
1SGD in Million2SGD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 175M | |
| 20.96x | 1.14x | 7.17x | 4.09% | 23.57B | |
| 23.61x | 2.38x | 11.4x | 2.24% | 20.58B | |
| 28.56x | 1.16x | 8.88x | 4.77% | 20.08B | |
| 22.69x | 2.39x | 9.95x | 1.75% | 6.66B | |
| 21.67x | 2.54x | 14.9x | 3.16% | 5.84B | |
| 14.16x | 1.26x | 7.31x | 3.8% | 5.59B | |
| 26.13x | 0.79x | 7.13x | 2.52% | 4.15B | |
| 22.72x | 1.3x | 9.4x | 2.2% | 3.77B | |
| 11.77x | 0.99x | 6.53x | 4.4% | 3.17B | |
| Average | 21.36x | 1.55x | 9.19x | 3.21% | 9.36B | |
| Weighted average by Cap. | 22.93x | 1.59x | 9.22x | 3.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- DM0 Stock
- Valuation Corporation Ltd.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
